ロード中...
Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib
Alectinib is approved and recommended as the preferred first‐line treatment for patients with anaplastic lymphoma kinase (ALK)‐positive non–small cell lung cancer. The effect of hepatic impairment on the pharmacokinetics (PK) of alectinib was assessed with physiologically based PK modeling prospecti...
保存先:
| 出版年: | J Clin Pharmacol |
|---|---|
| 主要な著者: | , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley and Sons Inc.
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6282775/ https://ncbi.nlm.nih.gov/pubmed/30052269 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.1286 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|